Clinical Drug Investigation

, Volume 38, Issue 5, pp 463–473 | Cite as

Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma

  • Julia Paik
  • Lesley J. Scott
  • Roy A. Pleasants
Adis Drug Evaluation


The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick®) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting β2-adrenoreceptor agonist (LABA) combination treatment is available in low-, mid- and high-dosage formulations (55/14, 113/14 and 232/14 μg, respectively). In 12-week, phase III trials in patients aged ≥ 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment produced significant improvements in lung function and other asthma symptoms compared with fluticasone propionate MDPI monotherapy or placebo MDPI. In a 26-week, phase III trial in this patient population, mid- and high-dosage fluticasone propionate/salmeterol MDPI were noninferior to mid- (250/50 μg) and high- (500/50 μg) dosage fluticasone propionate/salmeterol DPI (Advair Diskus®), respectively, in terms of improvements in lung function. Treatment-emergent adverse events (TEAEs) with fluticasone propionate/salmeterol MDPI were mostly of mild to moderate severity, with no severe TEAEs deemed to be treatment related. Although long-term pharmacovigilance is required to fully establish its safety, given the ease of use and favorable characteristics of the device and its clinical efficacy at relatively low metered doses of the active moieties, fluticasone propionate/salmeterol MDPI is an important emerging treatment option in patients aged ≥ 12 years with asthma.



During the peer review process, the manufacturer of fluticasone propionate/salmeterol MDPI was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

Roy Pleasants is a speaker for AstraZeneca and has received grants and/or consulting fees or honoraria from GlaxoSmithKline and Boehringer Ingelheim. Julia Paik and Lesley Scott are salaried employees of Adis/Springer and declare no relevant conflicts of interest.


  1. 1.
    Global Initiative for Athma. Global strategy for asthma management and prevention (2017 update). 2017. Accessed 22 Feb 2018.
  2. 2.
    Papi A, Haughney J, Virchow JC, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J. 2011;37(5):982–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–9.CrossRefPubMedGoogle Scholar
  4. 4.
    de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.CrossRefPubMedGoogle Scholar
  5. 5.
    Lewis A, Torvinen S, Dekhuijzen PNR, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017;129:179–88.CrossRefPubMedGoogle Scholar
  6. 6.
    Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–7.PubMedGoogle Scholar
  7. 7.
    Pleasants RA. Dry powder inhalers and humidity: another factor to consider to ensure adequate lung delivery. Ann Am Thorac Soc. 2017;14(10):1602.CrossRefPubMedGoogle Scholar
  8. 8.
    Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;104(9):1237–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Dekhuijzen PNR, Batsiou M, Bjermer L, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med. 2016;120:54–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Jones R, Martin J, Thomas V, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445–54.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Price D, Roche N, Christian Virchow J, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med. 2011;105(10):1457–66.CrossRefPubMedGoogle Scholar
  12. 12.
    Teva Respiratory LLC. AirDuo™ RespiClick®: US prescribing information. 2017. Accessed 22 Feb 2018.
  13. 13.
    US Center for Drug Evaluation and Research. Summary review (AirDuo RespiClick). 2017. Accessed 22 Feb 2018.
  14. 14.
    Raphael G, Yiu G, Sakov A, et al. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older. J Asthma. 2017. Scholar
  15. 15.
    Sher L, Yiu G, Sakov A, et al. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma. Allergy Asthma Proc. 2017;38:1–11.CrossRefGoogle Scholar
  16. 16.
    Mansfield L, Yiu G, Sakov A, et al. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. Allergy Asthma Proc. 2017;38(4):264–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Data on file, Teva Respiratory LLC, 2017.Google Scholar
  18. 18.
    Canonica GW, Arp J, Keegstra JR, et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015;28(5):309–19.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Janson C, Loof T, Telg G, et al. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016;26:16053.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Borgstrom L, Asking L, Lipniunas P. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J Aerosol Med. 2005;18(3):304–10.CrossRefPubMedGoogle Scholar
  21. 21.
    GlaxoSmithKline. Advair Diskus®: prescribing information. 2017. Accessed 22 Feb 2018.
  22. 22.
    Nugent C, Yiu G, Song S, et al. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma. J Asthma. 2017. Scholar
  23. 23.
    Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697–705.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kerwin EM, Gillespie M, Song S, et al. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids. J Asthma. 2017;54(1):89–98.CrossRefPubMedGoogle Scholar
  25. 25.
    Bernstein DI, Gillespie M, Song S, et al. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study. J Asthma. 2017;54(6):559–69.CrossRefPubMedGoogle Scholar
  26. 26.
    Miller DS, Yiu G, Hellriegel ET, et al. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016;37(4):291–301.CrossRefPubMedGoogle Scholar
  27. 27.
    Wlodarczyk JH, Gibson PG, Caeser M. Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. Ann Allergy Asthma Immunol. 2008;100(1):23–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Sim D, Griffiths A, Armstrong D, et al. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J. 2003;21(4):633–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Greenfield JR, Samaras K. Suppression of HPA axis in adults taking inhaled corticosteroids. Thorax. 2006;61(3):272–3.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol. 1998;53(6):459–67.CrossRefPubMedGoogle Scholar
  31. 31.
    US Food & Drug Administration. Long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS): Drug Safety Communication—boxed warning about asthma-related death removed. 2017. Accessed 22 Feb 2018.
  32. 32.
    Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med. 2016;375(9):840–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–9.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Given J, Taveras H, Iverson H. Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Allergy Asthma Proc. 2016;37(3):199–206.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Julia Paik
    • 1
  • Lesley J. Scott
    • 1
  • Roy A. Pleasants
    • 2
  1. 1.SpringerAucklandNew Zealand
  2. 2.Duke Clinical Research Institute and Durham Veterans Administration Medical CenterDurhamUSA

Personalised recommendations